News
![blueprint_logo](https://pharmaphorum.com/wp-content/uploads/2020/05/blueprint_logo.jpg)
Blueprint inks deal to buy lung cancer biotech Lengo
Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and its lead drug for lung cancer, a rival to already-approved thera